START- San Antonio

San Antonio, Texas 78229

32 studies enrolling now · 45 studies all time

What they study most

Acquired Resistance to KRAS G12C Inhibitor, Advanced Breast Cancer, Advanced Colorectal Cancer (Part 1), Advanced Solid Malignancies, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Solid Tumors, BRAF, BRAF Gene Mutation

Studies at this site

• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer — Recruiting now
• A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma — Recruiting now
• Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors — Recruiting now
• Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. — Recruiting now
• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — Recruiting now
• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors — Recruiting now
• A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors — Recruiting now
• ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours — Recruiting now
• Study of CHS-114 in Participants With Advanced Solid Tumors — Recruiting now
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors — Recruiting now
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors — Recruiting now
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors — Recruiting now
• Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer — Recruiting now
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies — Recruiting now
• Study of GS-5319 in Adults With Solid Tumors — Recruiting now
• A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) — Recruiting now
• A Study of Lorigerlimab in Participants With Advanced Solid Tumors — Recruiting now
• A Study of ZW251 in Participants With Advanced Solid Tumors — Recruiting now
• Study in Advanced Solid Tumor Patients — Recruiting now
• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — Recruiting now
• Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors — Recruiting now
• Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors — Recruiting now
• A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. — Recruiting now
• A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors — Recruiting now
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors — Recruiting now
• First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. — Recruiting now
• Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer — Starting soon
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies — Stopped early
• A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause — Completed
• A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors — Stopped early
• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors — Running, not enrolling
• A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. — Running, not enrolling
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. — Stopped early
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Running, not enrolling
• A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — Running, not enrolling
• A Study of ADRX-0706 in Select Advanced Solid Tumors — Running, not enrolling
• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors — Completed
• Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies — Running, not enrolling
• CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer — Running, not enrolling
• A Study of APX3330 in Patients With Advanced Solid Tumors — Completed